

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Schwers et al)	
)	
Serial No.:	10/525,278)	Examiner: S. Bausch
)	
Filed:	November 21, 2005)	Art Unit: 1634
)	
For	SINGLE NUCLEOTIDE POLYMORPHISMS)		
	SENSITIVELY PREDICTING ADVERSE)		
	DRUG REACTIONS (ADR) AND DRUG)		
	EFFICACY)		
)	

RESPONSE TO RESTRICTION REQUIRMENT**VIA EFS**

Commissioner for Patents
 PO BOX 1450
 Alexandria, VA 22313-1450

Sir:

In response to the restriction requirement dated March 26, 2008, applicants hereby provisionally elect the invention of Group 1 with traverse. Applicants note that claims 17-18 are linking claims which link the inventions of Groups 1-6. Upon allowance of linking claims 17 or 18, the restriction requirement will be withdrawn.

Further, applicants elect SEQ ID NOs: 469-42(baySNP11594) with traverse. Applicants submit that they are entitled to a reasonable number of species and, further, that the restriction requirement on page 6 of the outstanding restriction requirement should be an election of species requirement.

Respectfully submitted,

April 28, 2008
 Date

/karla m weyand/
 Karla M. Weyand
 Registration No. 40,223

Siemens Healthcare Diagnostics Inc
 511 Benedict Ave
 Tarrytown, New York 15091
 Tel: 914-524-2741